Advances in Precision Medicine Oncology
Recent advances in precision medicine and immuno-oncology have led to highly specific and efficacious cancer therapies such as monoclonal antibodies and immune checkpoint inhibitors (ICIs). This book provides an up-to-date overview of advances in the field of immuno-oncology. Chapters cover such top...
Saved in:
| Other Authors: | , |
|---|---|
| Format: | Electronic Book Chapter |
| Language: | English |
| Published: |
IntechOpen
2021
|
| Subjects: | |
| Online Access: | DOAB: download the publication DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000naaaa2200000uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_131078 | ||
| 005 | 20231201 | ||
| 003 | oapen | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 20231201s2021 xx |||||o ||| 0|eng d | ||
| 020 | |a intechopen.91507 | ||
| 020 | |a 9781839688683 | ||
| 020 | |a 9781839688676 | ||
| 020 | |a 9781839688690 | ||
| 040 | |a oapen |c oapen | ||
| 024 | 7 | |a 10.5772/intechopen.91507 |c doi | |
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a MJCL |2 bicssc | |
| 100 | 1 | |a Arnouk, Hilal |4 edt | |
| 700 | 1 | |a Abdul Rasool Hassan, Bassam |4 edt | |
| 700 | 1 | |a Arnouk, Hilal |4 oth | |
| 700 | 1 | |a Abdul Rasool Hassan, Bassam |4 oth | |
| 245 | 1 | 0 | |a Advances in Precision Medicine Oncology |
| 260 | |b IntechOpen |c 2021 | ||
| 300 | |a 1 electronic resource (260 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a Recent advances in precision medicine and immuno-oncology have led to highly specific and efficacious cancer therapies such as monoclonal antibodies and immune checkpoint inhibitors (ICIs). This book provides an up-to-date overview of advances in the field of immuno-oncology. Chapters cover such topics as ICIs and how they mount a robust immune response against cancer cells as well as the response of ICIs to treatment predictive biomarkers and their potential immune-related adverse events (irAEs). Additionally, the book includes a comprehensive review of the powerful FDA-approved therapeutic agent doxorubicin, highlighting the molecular mechanisms behind doxorubicin's drug resistance and critical side effects. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/3.0/ |2 cc |4 https://creativecommons.org/licenses/by/3.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Oncology |2 bicssc | |
| 653 | |a immunotherapy, doxorubicin, cancer immunotherapy, cancer, optimization, nanoparticles | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mts.intechopen.com/storage/books/10321/authors_book/authors_book.pdf |7 0 |z DOAB: download the publication |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/131078 |7 0 |z DOAB: description of the publication |